Business Description
Calliditas Therapeutics AB
ISIN : SE0010441584
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.01 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 2.89 | |||||
Debt-to-EBITDA | -4.74 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.61 | |||||
Beneish M-Score | -1.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 957.8 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | -2 | |||||
3-Year FCF Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -36.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 57.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.35 | |||||
9-Day RSI | 45.98 | |||||
14-Day RSI | 42.84 | |||||
6-1 Month Momentum % | 25.44 | |||||
12-1 Month Momentum % | -11.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.13 | |||||
Quick Ratio | 3.08 | |||||
Cash Ratio | 2.39 | |||||
Days Inventory | 102.5 | |||||
Days Sales Outstanding | 48.21 | |||||
Days Payable | 709.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -6.65 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.94 | |||||
Operating Margin % | -22.58 | |||||
Net Margin % | -27.44 | |||||
FCF Margin % | -19.49 | |||||
ROE % | -56.93 | |||||
ROA % | -15.63 | |||||
ROIC % | -42.51 | |||||
ROC (Joel Greenblatt) % | -444.94 | |||||
ROCE % | -14.13 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 714.29 | |||||
PS Ratio | 5.5 | |||||
PB Ratio | 16.69 | |||||
EV-to-EBIT | -27.21 | |||||
EV-to-Forward-EBIT | 68.92 | |||||
EV-to-EBITDA | -27.21 | |||||
EV-to-Forward-EBITDA | 68.92 | |||||
EV-to-Revenue | 5.45 | |||||
EV-to-Forward-Revenue | 2.85 | |||||
EV-to-FCF | -27.53 | |||||
Earnings Yield (Greenblatt) % | -3.67 | |||||
FCF Yield % | -3.65 |